La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Celon Pharma Crescita futura

Future criteri di controllo 4/6

Si prevede che Celon Pharma aumenterà gli utili e i ricavi rispettivamente del 108.5% e 7.4% all'anno, mentre si prevede che l'EPS crescerà del 85.8% all'anno.

Informazioni chiave

108.5%

Tasso di crescita degli utili

85.8%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	15.3%
Tasso di crescita dei ricavi	7.4%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	22 Jul 2024

Aggiornamenti recenti sulla crescita futura

Earnings Update: Celon Pharma S.A. (WSE:CLN) Just Reported And Analysts Are Boosting Their Estimates

Sep 24

Recent updates

A Piece Of The Puzzle Missing From Celon Pharma S.A.'s (WSE:CLN) Share Price

Aug 21

Earnings Update: Celon Pharma S.A. (WSE:CLN) Just Reported And Analysts Are Boosting Their Estimates

Sep 24

Celon Pharma S.A. (WSE:CLN) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?

Feb 09

Celon Pharma's (WSE:CLN) Earnings Are Growing But Is There More To The Story?

Jan 20

Celon Pharma (WSE:CLN) Shareholders Have Enjoyed A 12% Share Price Gain

Dec 24

Celon Pharma (WSE:CLN) Has A Pretty Healthy Balance Sheet

Dec 03

Previsioni di crescita degli utili e dei ricavi

WSE:CLN - Stime future degli analisti e dati finanziari passati (PLN Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	292	11	39	104	2
12/31/2025	282	4	11	48	3
12/31/2024	236	-14	6	36	2
3/31/2024	209	-34	-23	2	N/A
12/31/2023	214	-28	-41	-8	N/A
9/30/2023	214	-19	-31	7	N/A
6/30/2023	211	-24	-53	-16	N/A
3/31/2023	196	-41	-42	-8	N/A
12/31/2022	194	-39	-39	-5	N/A
9/30/2022	191	-31	-39	-10	N/A
6/30/2022	186	-28	-11	32	N/A
3/31/2022	191	-17	-17	25	N/A
12/31/2021	196	-12	3	44	N/A
9/30/2021	186	-11	7	60	N/A
6/30/2021	185	-2	3	57	N/A
3/31/2021	170	0	-18	71	N/A
12/31/2020	157	-1	-28	72	N/A
9/30/2020	142	4	-58	37	N/A
6/30/2020	128	5	-88	6	N/A
3/31/2020	109	3	-85	-19	N/A
12/31/2019	102	12	-70	-5	N/A
9/30/2019	110	17	-69	6	N/A
6/30/2019	118	23	-61	15	N/A
3/31/2019	124	29	-31	37	N/A
12/31/2018	125	30	-39	28	N/A
9/30/2018	116	30	-30	27	N/A
6/30/2018	109	26	-8	34	N/A
3/31/2018	107	28	-16	26	N/A
12/31/2017	107	26	N/A	25	N/A
9/30/2017	129	22	N/A	18	N/A
6/30/2017	127	24	N/A	23	N/A
3/31/2017	115	27	N/A	28	N/A
12/31/2016	129	38	N/A	21	N/A
9/30/2016	111	42	N/A	34	N/A
12/31/2015	108	37	N/A	52	N/A
12/31/2014	98	52	N/A	24	N/A
12/31/2013	72	18	N/A	8	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che CLN diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 3.9% ).

Guadagni vs Mercato: Si prevede che CLN diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.

Guadagni ad alta crescita: Si prevede CLN diventerà redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di CLN ( 7.4% all'anno) crescerà più rapidamente del mercato Polish ( 4.3% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di CLN ( 7.4% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di CLN è previsto essere elevato tra 3 anni

Celon Pharma Crescita futura

Future criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target increased by 26% to zł21.10

Consensus estimates of losses per share improve by 50%

Earnings Update: Celon Pharma S.A. (WSE:CLN) Just Reported And Analysts Are Boosting Their Estimates

Price target decreased to zł27.55

Price target decreased to zł27.55

Price target decreased to zł29.32

Recent updates

A Piece Of The Puzzle Missing From Celon Pharma S.A.'s (WSE:CLN) Share Price

New minor risk - Shareholder dilution

Price target increased by 26% to zł21.10

Celon Pharma S.A. Announces Strong Proof-Of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL'36), a Novel Oral Antipsychotic

Now 67% overvalued after recent price rise

Upcoming dividend of zł0.08 per share

Celon Pharma Announces Results of Phase Ii Clinical Trial for Cpl’ 116, A Jak/Rock Dual Inhibitor in the Treatment of Rheumatoid Arthritis (Ra)

Now 21% overvalued

Full year 2023 earnings released: zł0.55 loss per share (vs zł0.77 loss in FY 2022)

Consensus estimates of losses per share improve by 50%

Celon Pharma S.A. to Report Fiscal Year 2023 Results on Apr 24, 2024

Third quarter 2023 earnings released

Earnings Update: Celon Pharma S.A. (WSE:CLN) Just Reported And Analysts Are Boosting Their Estimates

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released

Celon Pharma (WSE:CLN) Is In A Good Position To Deliver On Growth Plans

Upcoming dividend of zł0.09 per share at 0.6% yield

Full year 2022 earnings released

Celon Pharma S.A. to Report Q3, 2023 Results on Nov 22, 2023

Third quarter 2022 earnings released

Price target decreased to zł27.55

We're Interested To See How Celon Pharma (WSE:CLN) Uses Its Cash Hoard To Grow

Price target decreased to zł27.55

Price target decreased to zł29.32

Second quarter 2022 earnings released

We Think Celon Pharma (WSE:CLN) Can Afford To Drive Business Growth

Consensus EPS estimates fall by 27%

Upcoming dividend of zł0.29 per share

Price target decreased to zł32.32

Consensus forecasts updated

Celon Pharma S.A., Annual General Meeting, Jun 22, 2022

Price target decreased to zł36.12

Consensus EPS estimates fall by 36%

Price target decreased to zł40.72

Price target decreased to zł43.23

Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to zł45.23

Price target decreased to zł48.23

Second quarter 2021 earnings released: EPS zł0.01 (vs zł0.25 in 2Q 2020)

Upcoming dividend of zł0.07 per share

Celon Pharma Files for Approval of Phase II Trial of CPL’280, a Second Generation GPR40 Agonist, in Type 2 Diabetes

Celon Pharma (WSE:CLN) Seems To Use Debt Quite Sensibly

Price target increased to zł54.07

Celon Pharma Terminates Cooperation with Lupin Atlantis Holdings

Calculating The Intrinsic Value Of Celon Pharma S.A. (WSE:CLN)

Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL’116, JAK-ROCK Inhibitor

Price target raised to zł50.30

Celon Pharma S.A. (WSE:CLN) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?

Celon Pharma S.A. to Report Fiscal Year 2020 Results on Mar 31, 2021

Celon Pharma S.A. to Report Q1, 2021 Results on May 31, 2021

Celon Pharma's (WSE:CLN) Earnings Are Growing But Is There More To The Story?

Celon Pharma Announces Positive Falkieri Phase II Results in Treatment-Resistant Bipolar Depression

Investor sentiment improved over the past week

New 90-day high: zł43.45

Celon Pharma (WSE:CLN) Shareholders Have Enjoyed A 12% Share Price Gain

Celon Pharma (WSE:CLN) Has A Pretty Healthy Balance Sheet

Third quarter 2020 earnings released: EPS zł0.088

Market bids up stock over the past week

New 90-day low: zł38.25

First half earnings released

New 90-day high - zł44.25

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita